Pharmacotherapy of Child and Adolescent Psychiatric Disorders, Third Edition

Description

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications. Third edition of the first ever book published on pediatric psychopharmacology from renowned editors. Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior. Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD. Features many tables, figures and pictorials, making it highly accessible and reader friendly. Content: Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology (pages 1–5): Samuel GershonChapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth (pages 7–23): Daniel J. Safer and Julie Magno ZitoChapter 3 Off?Label Prescribing of Drugs in Child and Adolescent Psychiatry (pages 25–38): C. Lindsay DevaneChapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology (pages 39–50): Richard I. Shader and Christopher?Paul MilneChapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology (pages 51–63): David J. EdwardsChapter 6 Psychostimulants (pages 65–104): Steven R. PliszkaChapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders (pages 105–129): Charlotte M. Heleniak, Tejal Kaur, Kareem D. Ghalib and Moira A. RynnChapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs) (pages 131–154): Dara Sakolsky and Boris BirmaherChapter 9 Novel (Atypical) Antidepressants (pages 155–179): Heidi R. Bruty, Graham J. Emslie and Paul CroarkinChapter 10 Antipsychotic Agents (pages 181–219): Brieana M. Rowles, John L. Hertzer and Robert L. FindlingChapter 11 Lithium (pages 221–259): Garrett M. Sparks and David A. AxelsonChapter 12 Anticonvulsants Used in Child and Adolescent Psychiatric Disorders (pages 261–299): Mani Pavuluri and Tushita MayanilChapter 13 Anxiolytics (pages 301–340): Barbara J. Coffey and Amanda L. ZwillingChapter 14 Adrenergic Agents in Child and Adolescent Psychiatry (pages 341–364): Lawrence David ScahillChapter 15 Atypical Psychopharmacologic Strategies (pages 365–397): Jess Shatkin and Aron JanssenChapter 16 Psychopharmacology in Preschool Children (pages 399–420): Mini Tandon and Joan LubyChapter 17 Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents (pages 421–438): Gagan Joshi and Anna M. Georgiopoulos